EpiThany Overview

  • Founded
  • 2014


  • Status
  • Private

  • Latest Deal Type
  • 2ndary - Private

EpiThany General Information


Developer of an anti-cancer immunotherapy treatment intended to treat patients with solid tumors. The company's immunotherapy focuses on developing tumor vaccines that drive Th1 (tumor-eradicating) immune responses without stimulating competitive Th2 (tumor-tolerant) responses, enabling physicians to target myriad tumor antigens across a spectrum of cancers, yielding a deep pipeline of Th1-selective anti-cancer vaccines.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • 3240 Fuhrman Avenue East
  • Suite 106
  • Seattle, WA 98102
  • United States
+1 (206) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

EpiThany Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Secondary Transaction - Private Completed Generating Revenue
1. Early Stage VC 01-Nov-2019 Completed Clinical Trials - Phase 1
To view EpiThany’s complete valuation and funding history, request access »

EpiThany Comparisons

HQ Location
Total Raised
Post Valuation
Developer of an anti-cancer immunotherapy treatment intended to treat patients with solid tumors. The company's immunoth
Drug Discovery
Seattle, WA
000000 - 000


ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercita
0000 000000000
Rockville, MD
00 As of 0000
0000000000 0 00000


d exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aut
0000 000000000
Emeryville, CA
000 As of 0000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

EpiThany Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Immunomic Therapeutics Venture Capital-Backed Rockville, MD 00 00000 0000000000 0 00000
000000000 000 Formerly VC-backed Emeryville, CA 000 00000 000000000 00000
000000 00000000000 Corporation Plymouth Meeting, PA 000 000.00 00000000 000.00
You’re viewing 3 of 3 competitors. Get the full list »

EpiThany Executive Team (3)

Name Title Board Seat Contact Info
David Poston President & Board Member
Mary Disis MD Scientific Co-Founder
You’re viewing 2 of 3 executive team members. Get the full list »

EpiThany Board Members (3)

Name Representing Role Since
David Poston EpiThany President & Board Member 000 0000
Martin Simonetti Sr. Self Board Member 000 0000
You’re viewing 2 of 3 board members. Get the full list »